Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 590 in Gilead Sciences

  1. RBC Capital Increases Gilead Sciences Price Target to $115.00Read the original story

    9 hrs ago | AmericanBankingNews.com

    ... RBC Capital's price target points to a potential upside of 10.62% from the company's current price. In other Gilead Sciences news, CFO Robin L. Washington sold 33,556 shares of the stock in a transaction that occurred on Thursday, August 14th. The ...

    Comment?

  2. June 30, 2014 Mid Year Mutual Fund ReviewRead the original story

    Yesterday | Value Line

    ... in research and development and business activities in the biotechnology sector. Current top holdings are Gilead Sciences Inc. Biogen Idec Inc. and Amgen Inc. Second best was the Franklin Biotechnology Discovery fund ( FBDIX ) posting a return of ...

    Comment?

  3. Jim Cramer's Stop Trading: Don't Worry About Gilead SciencesRead the original story w/Photo

    Thursday | TheStreet.com

    ... segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio , looked at shares of Gilead Sciences But Bernstein issued a report telling investors to stop with the worrying, and Cramer concurs. Competition likely won't be a ...

    Comment?

  4. Recent Analysts' Ratings Updates for Gilead SciencesRead the original story

    Wednesday Aug 20 | AmericanBankingNews.com

    A number of stock research firms have changed their ratings and price targets for Gilead Sciences during the last seven days: Gilead Sciences is now covered by analysts at Argus.

    Comment?

  5. $1,000 Sovaldi now hepatitis treatment of choiceRead the original story

    Wednesday Aug 20 | Foster's Daily Democrat

    ... clinical and commercial successes are also triggering scrutiny for the drug's manufacturer, California-based Gilead Sciences Inc., which just reported second-quarter profits of $3.66 billion, or a net margin of 56 percent. Two senators have ...

    Comment?

  6. Sanofi Wins U.S. Approval for Pill to Treat Rare Gaucher DiseaseRead the original story

    Tuesday Aug 19 | The Washington Post

    ... this in a way that does not bias the medical decision-making process," Meeker said. The $84,000 price tag on Gilead Sciences Inc.'s hepatitis C pill Sovaldi has raised the ire of health insurers and U.S. lawmakers who claim the cost for such a ...

    Comment?

  7. Pneumocystis jirovecii Pneumonia in Patients with or without AIDS, FranceRead the original story

    Tuesday Aug 19 | Centers for Disease Control and Prevention

    ... PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Gilead Sciences, Inc., Merck Sharp & Dohme Corp; served as a speaker or a member of a speakers bureau for Pfizer Inc, Merck Sharp & Dohme Corp; ...

    Comment?

  8. Aegerion Pharmaceuticals Is Still Significantly OvervaluedRead the original story

    Tuesday Aug 19 | Seeking Alpha

    ... of around 5. Considering that Aegerion is just relying on one drug, the valuation isn't justified. Indeed, Gilead Sciences Inc. (NASDAQ: GILD ), which expects sales of between $21 billion and $23 billion and has tremendous potential , has a ...

    Comment?

  9. 4 Large-Cap Healthcare Stocks To WatchRead the original story

    Monday Aug 18 | Investopedia

    ... is a good bet at any price, though. Here are four large-cap drug stocks to monitor for an entry point. Gilead Sciences Inc. ( GILD ) is charging at the $100 mark, closing at $99.49 on Aug. 15. Bursting out of small consolidation that contained the ...

    Comment?

  10. Achillion Pharmaceuticals Up On Buyout RumorsRead the original story

    Monday Aug 18 | Investor's Business Daily

    Achillion stock was up more than 2% in afternoon trading in the stock market today , near 9.50, after rising 9.6% on Friday.

    Comment?

  11. GlobeImmune, Inc. Announces Second Quarter 2014 Financial ResultsRead the original story

    Monday Aug 18 | BioSpace

    ... targeting brachyury. In October 2011, the Company entered into a worldwide, strategic collaboration with Gilead Sciences, Inc., to develop Tarmogens intended for the treatment of chronic hepatitis B infection. For additional information, please ...

    Comment?

  12. David Moon: Breakthrough pill presents puzzle The U.S. Centers for...Read the original story w/Photo

    Saturday Aug 16 | Knoxville News Sentinel

    The U.S. Centers for Disease Control and Prevention estimates there are 3.2 million Americans with chronic hepatitis C, 17,000 of whom will die this year as a result of the infection - a number that exceeds the annual deaths from HIV/AIDS in the U.S. Fortunately, Gilead Sciences produces a new breakthrough drug, Sovaldi, which has proved to cure 90 ... (more)

    Comment?

  13. Wall St ends mixed, recovers from Ukraine slideRead the original story w/Photo

    Saturday Aug 16 | Iol.co.za

    ... the Dow rose 0.7 percent, the S&P 500 gained 1.2 percent and the Nasdaq climbed 2.2 percent. The stock of Gilead Sciences Inc rose 3.3 percent to $99.49. Gilead contributed the most to the Nasdaq's gain, in terms of index points. The biotech company ...

    Comment?

  14. GlobeImmune Announces Second Quarter 2014 Financial ResultsRead the original story

    Friday Aug 15 | AndhraNews

    ... targeting brachyury. In October 2011, the Company entered into a worldwide, strategic collaboration with Gilead Sciences, Inc., to develop Tarmogens intended for the treatment of chronic hepatitis B infection. For additional information, please ...

    Comment?

  15. New Market Research Report: Pharmasset, Inc - Pharmaceuticals &...Read the original story

    Friday Aug 15 | PR-inside.com

    ... hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is a wholly-owned subsidiary of Gilead Sciences. The company's research and development activities are focused on a class of compounds known as nucleoside analogs, which act ...

    Comment?

  16. Biotech Leader Gilead Sciences Scores Sovald...Read the original story

    Friday Aug 15 | Investor's Business Daily

    Biotech firm Gilead Sciences rose sharply Friday, having touched a new high above 99, after it won a dispute with Roche over rights to its blockbuster hepatitis C drug, which separately was endorsed by the U.K.'s cost-benefit authority.

    Comment?

  17. STTG Market Recap August 15, 2014Read the original story

    Friday Aug 15 | Trader Mike

    ... Maybe this will be like VipShop (VIPS) which has been one of the more amazing stocks of the past 12+ months. Gilead Sciences (GILD) said that an arbitration panel ruled in its favor and rejected a patent infringement claim brought by Roche Holding. ...

    Comment?

  18. Us Stocks-Wall St ends mixed, recovers from Ukraine-driven slideRead the original story

    Friday Aug 15 | Reuters

    ... the Dow rose 0.7 percent, the S&P 500 gained 1.2 percent and the Nasdaq climbed 2.2 percent. The stock of Gilead Sciences Inc rose 3.3 percent to $99.49. Gilead contributed the most to the Nasdaq's gain, in terms of index points. The biotech company ...

    Comment?

  19. Achillion Rises on Hepatitis C Drug StudyRead the original story w/Photo

    Friday Aug 15 | Pharmaceutical Processing

    ... trial had undetectable levels of the hepatitis C virus after eight weeks of treatment with ACH-3102 and Gilead Sciences' drug Sovaldi. The virus was not detectable in the patients' bodies four weeks after their treatment ended. Based on the results, ...

    Comment?

  20. A Double Dose of Good News for Gilead Sciences, Inc.Read the original story w/Photo

    Friday Aug 15 | The Motley Fool

    Not only has the biotech's hepatitis C treatment Sovaldi become a multibillion-dollar drug less than a year into its launch, but Gilead got two pieces of good news today in the announcements of a positive result from a lawsuit and coverage of Sovaldi by the U.K.'s National Institute for Health and Care Excellence, or NICE.

    Comment?